-
Signature
-
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill
-
Issuer symbol
-
PTGX
-
Transactions as of
-
10 Oct 2025
-
Net transactions value
-
-$895,720
-
Form type
-
4
-
Filing time
-
14 Oct 2025, 16:01:11 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Waddill William D. |
Director |
C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK |
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill |
14 Oct 2025 |
0001553338 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PTGX |
Common Stock |
Options Exercise |
$83,760 |
+12,000 |
+234% |
$6.98 |
17,130 |
10 Oct 2025 |
Direct |
|
| transaction |
PTGX |
Common Stock |
Sale |
$277,000 |
-4,000 |
-23% |
$69.25 |
13,130 |
10 Oct 2025 |
Direct |
F1 |
| transaction |
PTGX |
Common Stock |
Sale |
$702,480 |
-8,000 |
-61% |
$87.81 |
5,130 |
10 Oct 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
PTGX |
Stock Option (right to buy) |
Options Exercise |
$0 |
-12,000 |
-100% |
$0.000000 |
0 |
10 Oct 2025 |
Common Stock |
12,000 |
$6.98 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: